摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯-5-(2-氟苯基)-1H-吡咯-3-羧酸乙酯 | 881674-01-7

中文名称
2-氯-5-(2-氟苯基)-1H-吡咯-3-羧酸乙酯
中文别名
——
英文名称
ethyl 2-chloro-5-(2-fluorophenyl)-1H-pyrrole-3-carboxylate
英文别名
——
2-氯-5-(2-氟苯基)-1H-吡咯-3-羧酸乙酯化学式
CAS
881674-01-7
化学式
C13H11ClFNO2
mdl
——
分子量
267.687
InChiKey
XKHNEVMEVCRYQH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    454.0±45.0 °C(Predicted)
  • 密度:
    1.314±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    42.1
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:1fd5c869ce9b0e10b4ec571b2fc25c52
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-氯-5-(2-氟苯基)-1H-吡咯-3-羧酸乙酯 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 、 二异丁基氢化铝 作用下, 以 四氢呋喃乙醇甲苯 、 mineral oil 为溶剂, 反应 42.67h, 生成 5-(2-氟苯基)-1-[(吡啶-3-基)磺酰基]-1H-吡咯-3-甲醛
    参考文献:
    名称:
    Proton pump inhibitors
    摘要:
    公开号:
    EP2336107B1
  • 作为产物:
    描述:
    参考文献:
    名称:
    鉴定新型氟吡咯衍生物作为具有长效作用的钾竞争性酸阻滞剂。
    摘要:
    为了找到一种新型的,持久的钾竞争性酸阻滞剂(P-CAB),可以完全克服质子泵抑制剂(PPI)的局限性,我们尝试了以吡咯衍生物1b为先导化合物的各种方法。作为鉴定新药的综合方法的一部分,我们通过在吡咯环的5位引入极性杂芳族基团,探索了具有低亲脂性的出色化合物。在合成的化合物中,氟吡咯衍生物37c在第五位具有2-F-3-Py基团,其pKa较低,并且ClogP和logD值比1b剂量低,它们显示出有效的胃酸抑制作用,这是由于胃H + ,K + -ATPase在动物模型中的抑制。在大鼠中,其最大胃内pH升高作用很强,而且它的作用持续时间比兰索拉唑或铅化合物1b对狗的作用时间长得多。因此,化合物37c可以被认为是具有长效作用的有前途的新P-CAB。
    DOI:
    10.1016/j.bmc.2017.04.014
点击查看最新优质反应信息

文献信息

  • [EN] PROTON PUMP INHIBITORS<br/>[FR] INHIBITEURS DE POMPE A PROTONS
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2006036024A1
    公开(公告)日:2006-04-06
    Proton pump inhibitors which have excellent proton pumping activity and which can be converted in vivo into proton pump inhibitors to exhibit antiulcer effect and so on, containing compounds represented by the general formula (I) or salts thereof or prodrugs of the same: (I) wherein X and Y are each independently a free valency or a spacer whose main chain has 1 to 20 carbon atoms; R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; R2, R3 and R4 are each independently hydrogen, an optionally substituted hydrocarbon group, optionally substituted thienyl, optionally substituted benzo[b]thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrazolyl, optionally substituted pyrimidinyl, acyl, halogeno, cyano, or nitro; and R5 and R6 are each independently hydrogen or an optionally substituted hydrocarbon group.
    质子泵抑制剂具有优异的质子泵活性,可以在体内转化为质子泵抑制剂,表现出抗溃疡作用等,包含由通式(I)表示的化合物或其盐或类似物:(I)其中X和Y分别是自由价或其主链具有1至20个碳原子的间隔物;R1是可选择地取代的碳氢基团或可选择地取代的杂环基团;R2、R3和R4分别是氢、可选择地取代的碳氢基团、可选择地取代的噻吩基、可选择地取代的苯并[b]噻吩基、可选择地取代的呋喃基、可选择地取代的吡啶基、可选择地取代的吡唑基、可选择地取代的嘧啶基、酰基、卤素、氰基或硝基;R5和R6分别是氢或可选择地取代的碳氢基团。
  • Acid secretion inhibitor
    申请人:Kajino Masahiro
    公开号:US20070060623A1
    公开(公告)日:2007-03-15
    The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R 1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R 2 is an optionally substituted C 6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R 3 and R 4 are each a hydrogen atom, or one of R 3 and R 4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R 5 is an alkyl group or a salt thereof.
    本发明提供一种具有优越的抑制酸分泌作用并显示抗溃疡活性等的化合物。本发明提供一种由式(I)表示的化合物,其中R1是一种含氮的单环杂环基,可选择地与苯环或杂环缩合,该含氮的单环杂环基可选择地与苯环或杂环缩合,可选择地具有取代基,R2是可选择地取代的C6-14芳基,可选择地取代的噻吩基或可选择地取代的吡啶基,R3和R4分别是氢原子,或者R3和R4中的一个是氢原子,另一个是可选择地取代的较低烷基基团、酰基、卤原子、氰基或硝基,R5是烷基或其盐。
  • Identification, characterization, synthesis of major metabolites biotransformed from vonoprazan fumarate
    作者:Biyue Lin、Jingping Kou、Qingbo Xiao、Shuming Wu、Ji'an Hu、Jianbing Li、Zhu Zhu、Xinglin Zhou、Libo Xin、Yanhua Li、Zhongqing Wang
    DOI:10.1016/j.tet.2022.132669
    日期:2022.2
    A first synthetic research concerning four observed metabolites and their deuterium-labeled analogues of reflux esophagitis drug vonoprazan fumarate is reported. Among which the synthetic methods of three metabolites M − I, M-III, M-IV-Sul, and four stable isotop labeled analogues M-I-d4, M-II-d4, M-III-d4, M-IV-Sul-d4 have not yet been reported before. The structures of these compounds were elucidated
    报道了关于四种观察到的代谢物及其氘标记的反流性食管炎药物沃诺拉赞富马酸盐类似物的首次合成研究。其中三种代谢物M-I、M-III、M-IV-Sul和四种稳定同位素标记的类似物MI - d 4、M-II -d 4、M-III -d 4、M-IV的合成方法-Sul -d 4之前还没有报道过。基于 MS 和 NMR 光谱阐明了这些化合物的结构。
  • 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR
    申请人:Kajino Masahiro
    公开号:US20090275591A1
    公开(公告)日:2009-11-05
    The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R 1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R 2 is an optionally substituted C 6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R 3 and R 4 are each a hydrogen atom, or one of R 3 and R 4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R 5 is an alkyl group or a salt thereof.
    本发明提供一种具有优异的抑制酸分泌作用并具有抗溃疡活性等的化合物。本发明提供一种由式(I)表示的化合物,其中R1是一种含氮的单环杂环基,可选择与苯环或杂环缩合,该含氮的单环杂环基可选择与苯环或杂环具有取代基,R2是可选择取代的C6-14芳基、可选择取代的噻吩基或可选择取代的吡啶基,R3和R4分别是氢原子,或者R3和R4中的一个是氢原子,另一个是可选择取代的低碳基、酰基、卤素原子、氰基或硝基,R5是烷基或其盐。
  • Proton Pump Inhibitors
    申请人:Kajino Masahiro
    公开号:US20080139639A1
    公开(公告)日:2008-06-12
    A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R 2 , R 3 and R 4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R 5 and R 6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.
    提供一种质子泵抑制剂,其中包含公式(I)所代表的化合物,其中X和Y相同或不同,每个都是具有1到20个碳原子的主链中的键或间隔物,R1是可选取代的碳氢化合物基团或可选取代的杂环基团,R2、R3和R4相同或不同,每个都是氢原子、可选取代的碳氢化合物基团、可选取代的噻吩基团、可选取代的苯并[b]噻吩基团、可选取代的呋喃基团、可选取代的吡啶基团、可选取代的吡唑基团、可选取代的嘧啶基团、酰基、卤素原子、氰基或硝基,R5和R6相同或不同,每个都是氢原子或可选取代的碳氢化合物基团。该化合物在体内转化为质子泵抑制剂后具有卓越的质子泵作用,并显示抗溃疡活性等,或其盐或前药。
查看更多